1

2

7

A non-competing pair of human neutralizing antibodies block

COVID-19 virus binding to its receptor ACE2

- 3 Yan Wu^{1,2,#,*}, Feiran Wang^{3,4,#}, Chenguang Shen^{3,5,#}, Weiyu Peng^{3,6,#}, Delin Li^{3,5,7,#},
- 4 Cheng Zhao^{3,8}, Zhaohui Li^{3,9}, Shihua Li³, Yuhai Bi^{3,10}, Yang Yang⁵, Yuhuan Gong^{3,10},
- 5 Haixia Xiao⁷, Zheng Fan³, Shuguang Tan³, Guizhen Wu¹¹, Wenjie Tan¹¹, Xuancheng
- 6 Lu¹², Changfa Fan¹³, Qihui Wang³, Yingxia Liu⁵, Chen Zhang¹, Jianxun Qi³, George

8 Affiliations:

- ⁹ ¹Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital
- 10 Medical University, Beijing, China.

Fu Gao^{3,*}, Feng Gao^{7,*}, Lei Liu^{5,*}

- ¹¹ ²Research Network of Immunity and Health (RNIH), Beijing Institutes of Life
- 12 Science, Chinese Academy of Sciences, Beijing, China
- ¹³ ³CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of
- 14 Microbiology, Chinese Academy of Sciences, Beijing, China.
- ⁴School of Life Sciences, University of Science and Technology of China, Hefei,
- 16 Anhui 230026, China.
- ¹⁷ ⁵Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's
- 18 Hospital, Shenzhen 518112, China.
- ¹⁹ ⁶College of Veterinary Medicine, China Agricultural University, Beijing, China.
- ²⁰ ⁷Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial
- 21 Biotechnology, Chinese Academy of Sciences, Tianjin, China
- ²² ⁸Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China

23	⁹ University of	Chinese Academ	y of Sciences,	Beijing	100049,	China
	2		· · · · · · · · · · · · · · · · · · ·	50		

- ²⁴ ¹⁰Center for Influenza Research and Early Warning, Chinese Academy of Sciences
- 25 (CASCIRE), Beijing 100101, China
- ²⁶ ¹¹NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and
- 27 Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
- ²⁸ ¹²Laboratory Animal Center, Chinese Center for Disease Control and Prevention,
- 29 Beijing, China
- ³⁰ ¹³Division of Animal Model Research, Institute for Laboratory Animal Resources,
- 31 National Institutes for Food and Drug Control, Beijing, China
- 32
- 33 #These authors contributed equally.
- 34 *Correspondence: wuy@biols.ac.cn (Y.W.); gaofeng@tib.cas.cn (F.G.),
- 35 gaof@im.ac.cn (G.F.G.), liulei3322@aliyun.com (L.L.)
- 36

37 Abstract

Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we 38 report the isolation of four human-origin monoclonal antibodies from a convalescent 39 patient in China. All of these isolated antibodies display neutralization abilities in vitro. 40 Two of them (B38 and H4) block the binding between RBD and vial cellular receptor 41 42 ACE2. Further competition assay indicates that B38 and H4 recognize different 43 epitopes on the RBD, which is ideal for a virus-targeting mAb-pair to avoid immune 44 escape in the future clinical applications. Moreover, therapeutic study on the mouse 45 model validated that these two antibodies can reduce virus titers in the infected mouse 46 lungs. Structure of RBD-B38 complex revealed that most residues on the epitope are 47 overlapped with the RBD-ACE2 binding interface, which explained the blocking efficacy and neutralizing capacity. Our results highlight the promise of antibody-based 48 49 therapeutics and provide the structural basis of rational vaccine design.

50 **One Sentence Summary:** A pair of human neutralizing monoclonal antibodies against 51 COVID-19 compete cellular receptor binding but with different epitopes, and with 52 post-exposure viral load reduction activity.

53 **Main Text:** The COVID-19 caused by the novel coronavirus COVID-19 virus has 54 become a global health crisis. The virus has spread worldwide, causing fever, severe 55 respiratory illness and pneumonia(1, 2). Phylogenetic analysis indicates that the 56 emerging pathogen is closely related to several bat coronaviruses and to severe acute 57 respiratory syndrome coronavirus (SARS-CoV)(3-5). It is worth to note that 58 COVID-19 virus appears to be more easily transmitted from person to person(6). To

date, however, no specific drugs or vaccines are available so far, except for several
general antiviral drugs (eg. Remdesivir and hydroxychloroquine, et al.) under clinical
investigation.

62 COVID-19 virus belongs to betacoronavirus genus, in which five human infected 63 pathogens are implicated (7, 8). Among them, SARS-CoV and Middle East respiratory 64 syndrome coronavirus (MERS-CoV) are two highly pathogenic viruses. As with other 65 coronaviruses, the spike glycoprotein (S) homotrimer on the COVID-19 virus surface 66 plays an essential role in receptor binding, triggering the cell membrane fusion for virus 67 entry. The S protein is a class I fusion protein and each S protomer consists of S1 and 68 S2 domains(9). The receptor binding domain (RBD) locates on the S1 region(8). 69 Previous studies revealed that COVID-19 virus infects host cells by using the same 70 receptor ACE2 as SARS-CoV for entry(3, 10-12), and the RBD undergoes hinge-like 71conformational movements to engage ACE2 binding(13). Numerous neutralizing 72 antibodies targeting RBD of either SARS-CoV or MERS have been identified(14-16). 73 Therefore, screening the neutralizing antibodies against COVID-19 virus by using the 74 RBD protein is the priority strategy.

We expressed COVID-19 virus RBD protein as a bait to isolate the specific single memory B-cells from peripheral blood mononuclear cells (PBMCs) of a convalescent COVID-19 patient. The variable regions encoding the heavy chain and light chain were amplified from single B cells, respectively, and were then cloned into pCAGGS vector with the constant region to produce IgG1 antibodies as previous described(*17*). 17 paired B cell clones were amplified and 3 of which were identical (B5, B59 and H1). To

81	identify the binding abilities of these antibodies, the plasmids containing the paired
82	heavy chain and light chains were co-transfected into HEK 293T cells for monoclonal
83	antibodies (mAbs) production. The supernatants were then screened for binding to
84	COVID-19 virus RBD by Bio-Layer Interferometry (BLI) in OctetRED96, and an
85	irrelevant anti-SFTSV Gn antibody and a SARS-CoV specific antibody were used as
86	controls. The supernatants from four different antibodies (B5, B38, H2 and H4) exhibit
87	the binding abilities to COVID-19 virus RBD, but failed binding to SARS-CoV RBD
88	(Figure S1), suggesting that the epitope between SARS-CoV and COVID-19 virus
89	RBDs are immunologically distinct. The usage of both heavy chain (V _H) and light
90	chain (V _L) variable genes are listed in Table S1.

We then further measured the binding kinetics using surface plasmon resonance (SPR). 91 92 These four antibodies displayed various binding abilities to COVID-19 virus RBD, with K_d ranging from 10⁻⁷ to 10⁻⁹ M (Figure 1 A-D). H4 presented relatively higher 93 binding affinity, with K_d of 4.48 nM, while B5 displayed relatively weaker binding 94 affinity, with K_d of 305 nM. B38 and H2 bind to RBD, with K_d of 70.1 nM and 14.3 nM, 95 96 respectively. We next studied the neutralizing activities against COVID-19 virus virus 97 (BetaCoV/Shenzhen/SZTH-003/2020). All these four antibodies exhibit neutralizing 98 activities, with IC₅₀ values ranging from 0.177 μ g/ml to 1.375 μ g/ml (Figure 2). B38 99 was the most potent antibody, followed by H4, H2 and B5. Combined with the results 100 of the competitive binding assay, it is suggested that different mAbs may exert 101 neutralizing activities through distinct mechanisms.

102	To evaluate the competition abilities of each antibody for blocking the binding between
103	viral RBD and ACE2, we performed the competition assay by using BLI in
104	OctetRED96 and a blocking assay by using fluorescence-activated cell sorting (FACS).
105	Specifically, the streptavidin biosensors labelled with biotinylated RBD were saturated
106	with antibodies, and then flowed through with the test antibodies in the presence of
107	soluble ACE2. B38 and H4 showed completely competition with ACE2 for the binding
108	to RBD. In contrast, B5 displayed partial competition, while H2 show no competition
109	with ACE2 for the RBD binding (Figure 1 E-H). The blocking assay by FACS
110	presented similar results. Specifically, the ACE2-EGFP proteins were presented on the
111	cell surface by transfection of ACE2-EGFP plasmid into HEK 293T cells, and then
112	stained with RBD-histag proteins (positive control) or the preincubated RBD-antibody
113	mixture. Both B38 and H4 can block the binding between RBD and ACE2 (Figure1I),
114	suggesting that the epitopes of these two antibodies locate on the RBD-ACE2 binding
115	interface. To determine whether B38 and H4 target the same epitope, the epitope
116	competition assay was performed with BLI. The viral RBD immobilized on the
117	Ni-NTA sensor was first saturated with B38 IgG and flowed through B38 IgG in the
118	presence or absence of H4 IgG, and vice versa. The result indicated that although
119	RBD was saturated with the first antibody, the second antibody can still bind to RBD,
120	suggesting that B38 and H4 recognize different epitopes on RBD with partial
121	overlapping (Figure1 J-K).

To explore the protection efficacy of B38 and H4 against challenge with COVID-19
virus *in vivo*, therapeutic study was performed. hACE2 transgenic mice were

124 administered with a single dose of 25 mg/kg of B38 or H4 12 hours after virus 125 challenge. The results revealed that the body weight of B38 group substantially 126 decreased and recovered at 3 days post infection (dpi) compared with PBS control 127 group and H4 group (Figure 3A). The viral RNA copies of lung tissue were also 128 detected at 3 dpi. The relative RNA copies change of both B38 group and H4 group 129 were significantly lower than that of the PBS group, with a reduction of 32.8% and 26% 130 RNA copies change of that in PBS group, respectively (Figure 3B). These results 131 exhibit the identical trends to the neutralization abilities.

132 To further elucidate the structural basis of the neutralization mechanisms of the 133 antibodies, we prepared both the RBD-B38 and RBD-H4 Fab complexes by 134 incubating the two proteins *in vitro* and then purified with a gel filtration column. 135 Consistent with the binding affinity between viral RBD and B38 or H4, the stable 136 complex was obtained (Figure S2). We therefore determined the crystal structure of B38 Fab with the viral RBD at 1.9 Å resolution (Table S2). Three 137 138 complementarity-determining regions (CDRs) on the heavy chain (HCDR) and two 139 CDRs on the light chain (LCDR) are involved in interaction with the viral RBD 140 (Figure 4A and B). The buried surface area of heavy chain and light chain on the epitope is 713.9 Å and 497.7 Å, respectively. There are 36 residues in viral RBD 141 142 involved in the interaction with B38, of which 21 residues and 15 residues interact 143 with heavy chain and light chain, respectively (Table S3 and Figure 4B). Sequence 144 alignment indicates that only 15 of the 36 residues in the epitope (defined as residues 145 buried by B38) are conserved between COVID-19 virus and SARS-CoV (Figure 4D,

146	4F, and S3). This explains the specific reactivity of B38. Hydrophilic interactions are
147	the major interacting forces on the interface between B38 and viral RBD (Table S4).
148	Further analysis of the interactions of the binding interface reveals that the 470-loop
149	of viral RBD plays an important role in binding to B38 HCDR1 loop (Figure 4G).
150	The conformation of 470-loop is supported by Q474. In contrast, the corresponding
151	loop (460-loop) in SARS-RBD displays distinct conformation due to the β -turn
152	formed by P462 and G464, which is unfit for HCDR1 binding. S30 and S31 form
153	hydrogen bonds to the side chain of K458, while the corresponding residue H445 in
154	SARS-CoV RBD loses the interactions (Figure 4G). For the residues on contacting
155	with the HCDR2, K417 is the only different residue between two RBDs involved in
156	the interactions. The corresponding residue V404 in the SARS-CoV RBD loses the
157	hydrogen bond to Y52, and the conformational change of the threonine results in
158	losing the interaction with Y58 side chain (Figure 4H). Notably, the interactions
159	between the side chains of two residues (Y100 and D103) on the HCDR3 and
160	COVID-19 virus RBD are mediated by water molecules (Figure 4I). Specifically, the
161	oxygen atom on the hydroxyl group interacts with E484, F490, L492 and Q493 on
162	RBD via two water molecules. The side chain of D103 on the HCDR3 interacts with
163	Y489 through a water molecule. Residue R97 on the HCDR3 hydrogen bonds to the
164	side chains of both Y489 and N487. For the corresponding residues involved in the
165	interactions with HCDR3 in SARS-CoV RBD, four residues are not conserved (N487,
166	Y489, P491 and L492). P469 and W476 (corresponding residues F490 and E484 in
167	COVID-19 virus RBD) are two unconserved residues between these two RBDs. E484

168	provides a polar contact with Y100 through water molecule, while P469 and W476 in
169	SARS-CoV RBD are hydrophobic residues, which may be unsuitable for antibody
170	binding. By contrast, residues involved in the interactions with LCDR loops between
171	COVID-19 virus RBD and SARS-CoV RBD are more conserved (Figure 4J and K).
172	Although two residues involved in the binding to LCDR3 loop are different between
173	these two RBDs, they have the same properties (R403 and E406 in COVID-19 virus
174	RBD, the corresponding residues are K491 and D493 in SARS-CoV RBD). This
175	perfectly explains the B38 specific binding to COVID-19 rather than SARS-CoV.
176	To explore the structural basis for B38 blocking the interaction between COVID-19
177	virus RBD and ACE2, the complex structures of COVID-19 virus RBD/B38-Fab and
178	COVID-19 virus RBD/hACE2 were superimposed. Both the $V_{\rm H}$ and $V_{\rm L}$ of B38 result
179	in steric hindrance to the RBD binding to ACE2 (Figure 4C). Notably, the RBDs in
180	B38-bound form and hACE2-bound form exhibit no significant conformational
181	changes with the Ca root mean squared deviation (RMSD) of 0.489 Å (for 194 atoms).
182	Further analysis indicated that 18 of the 21 amino acids on RBD are identical in
183	binding B38 and ACE2 (Figure 4D), which clearly explains why B38 completely
184	abolish the binding between COVID-19 virus RBD and the receptor.
185	COVID-19 virus and SARS-CoV RBDs share relatively high identity, and both of
186	them bind to receptor ACE2 for entry. However, the binding affinities are different.
187	COVID-19 virus RBD exhibits higher binding affinity for receptor binding because of
188	more atomic interactions with hACE2 than that of SARS-CoV RBD. Consequently,
189	the different amino acids located on the hACE2 binding interface may lead to the

190 generation of specific neutralizing antibodies in the host. So far, no antibody has been 191 reported to cross-neutralize both SARS-CoV2 and SARS-CoV by competing the 192 ACE2 binding site. CR3022 derived from a convalescent SARS patient can bind to 193 RBDs from both viruses(18). However, it enables neutralizing SARS-CoV, but not 194 COVID-19 virus. The epitope of CR3022 does not overlap with the ACE2-binding 195 site(19), suggesting that it may be difficult to achieve cross-reactive neutralizing 196 antibodies that can compete with ACE2 binding. A comprehensive understanding of 197 the humoral immune responses against COVID-19 virus should be investigated in 198 more patients. In addition, cocktail antibodies should be considered as an alternative 199 therapeutic strategy to avoid potential escape mutants.

As the COVID-19 outbreak continues to spread, characterization of the epitopes on COVID-19 virus RBD protein is essential, which will provide valuable information to develop vaccines. Furthermore, the molecular features of the neutralizing antibodies targeting epitopes are helpful for the development of small molecule or peptide drugs/inhibitors. In conclusion, the neutralizing antibodies identified here are promising candidates for prophylactic and therapeutic treatment against COVID-19 virus.

207

208 **References and notes**

- N. Zhu *et al.*, A Novel Coronavirus from Patients with Pneumonia in China,
 2019. *N Engl J Med*, (2020).
- 211 2. C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak
 212 of global health concern. *Lancet* 395, 470-473 (2020).
- 213 3. P. Zhou, Yang, X.L., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B.,

- 214 Chen, J., Luo, H., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., 215 Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Yan, B., Wang, Y.Y., 216 Xiao, G.F., Shi, Z.L., A pneumonia outbreak associated with a new 217 coronavirus of probable bat origin. *Nature*, (2020). 218 4. W. Tan *et al.*, Notes from the Field: A novel coronavirus genome identified in 219 a cluster of pneumonia cases-Wuhan, China 2019-2020. China CDC weekly 2, 220 2 (2020). 221 5. R. Lu et al., Genomic characterisation and epidemiology of 2019 novel 222 coronavirus: implications for virus origins and receptor binding. *Lancet* 395, 223565-574 (2020). 224 6. J. F. Chan et al., A familial cluster of pneumonia associated with the 2019 225 novel coronavirus indicating person-to-person transmission: a study of a 226 family cluster. Lancet 395, 514-523 (2020). 2277. F. Wu et al., A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269 (2020). 228 2298. G. Lu, Q. Wang, G. F. Gao, Bat-to-human: spike features determining 'host 230 jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends 231*Microbiol* 23, 468-478 (2015). 9. D. M. Knipe, P. M. Howley, Fields virology. (Wolters Kluwer/Lippincott 232233 Williams & Wilkins Health, Philadelphia, PA, ed. 6th, 2013), pp. 2 volumes. 10. A. C. Walls et al., Structure, Function, and Antigenicity of the SARS-CoV-2 234 235Spike Glycoprotein. Cell, (2020). M. Hoffmann et al., SARS-CoV-2 Cell Entry Depends on ACE2 and 236 11. 237 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 238 (2020).239 12. Q. Wang et al., Structural and Functional Basis of SARS-CoV-2 Entry by 240 Using Human ACE2. Cell, (2020). D. Wrapp et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion 241 13. 242 conformation. Science 367, 1260-1263 (2020). 14. Y. Zhou, Y. Yang, J. Huang, S. Jiang, L. Du, Advances in MERS-CoV 243
 - 11

- Vaccines and Therapeutics Based on the Receptor-Binding Domain. *Viruses* 11,
 (2019).
- L. Du *et al.*, MERS-CoV spike protein: a key target for antivirals. *Expert Opin Ther Targets* 21, 131-143 (2017).
- L. Du *et al.*, The spike protein of SARS-CoV--a target for vaccine and
 therapeutic development. *Nat Rev. Microbiol* 7, 226-236 (2009).
- Q. Wang *et al.*, Neutralization mechanism of human monoclonal antibodies
 against Rift Valley fever virus. *Nat Microbiol* 4, 1231-1241 (2019).
- X. Tian *et al.*, Potent binding of 2019 novel coronavirus spike protein by a
 SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes & Infect* 9, 382-385 (2020).
- M. Yuan *et al.*, A highly conserved cryptic epitope in the receptor-binding
 domains of SARS-CoV-2 and SARS-CoV. *Science*, (2020).
- 257 20. Q. Wang *et al.*, Neutralization mechanism of human monoclonal antibodies
 258 against Rift Valley fever virus. *Nat Microbiol* 4, 1231-1241 (2019).
- Z. Otwinowski, Minor, W. & Charles W. Carter, Jr., Processing of X-ray
 diffraction data collected in oscillation mode. *Methods Enzymol* 276, 307-326
 (1997).
- 262 22. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics.
 263 Acta Crystallogr D Biol Crystallogr 60, 2126-2132 (2004).
- 264 23. P. D. Adams *et al.*, PHENIX: building new software for automated
 265 crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*266 58, 1948-1954 (2002).
- 267 24. C. J. Williams *et al.*, MolProbity: More and better reference data for improved
 268 all-atom structure validation. *Protein Sci* 27, 293-315 (2018).
- 269

270 Materials and Methods

271 Ethics statement

All procedures in this study involving authentic COVID-19 virus were performed in biosafety level 3 (BSL-3) facility. Murine studies were performed in an animal biosafety level 3 (ABSL-3) facility. All the procedures in the murine study were reviewed and approved by the Laboratory Animal Welfare and Ethics Committee in Chinese Academy of Sciences. The donor provided written informed consent for the use of blood and blood components followed the approval from the Research Ethics Committee of ShenZhen Third People's Hospital, China.

279 Cells and Viruses

HEK293T (ATCC CRL-3216) cells and Vero (ATCC CCL-81TM) cells were cultured 280 281 at 37 \square with 5% CO₂ in Dulbecco's Modified Eagle medium (DMEM) supplemented 10% 282 with fetal bovine serum (FBS). COVID-19 virus strain 283 BetaCoV/shenzhen/SZTH-003/2020 (GISAID ID: EPI_ISL_406594) used in 284 neutralization assay was isolated from the patient in Shenzhen Key Laboratory of 285 Pathogen and Immunity, Shenzhen Third Peoples' Hospital. COVID-19 virus strain 286 HB-01 used in the animal experiment was provided by Professor Wenjie Tan from 287 Chinese center for disease control and prevention. Vero E6 cells were applied to the 288 amplification and titer titration of the virus stocks.

289 Gene construction

The recombinant protein COVID-19 virus RBD was constructed into two vectors. Residues 331-532 (accession number EPI_ISL_402119) were cloned into pET21a for isolating mAbs as a bait. The coding sequences of COVID-19 RBD (residues 331-532),

SARS-CoV RBD (residues 306-527, accession number NC_004718), and hACE2 (residues 19-615, accession number BAJ21180) were used in assays of SPR, BLI and crystal screening were constructed into pFastBac1 plasmid with an N-terminal gp67 signal peptide and a C-terminal six histidine tag. The pEGFP-N1-hACE2 plasmid was constructed by cloning the coding region into pEGFP-N1 vector using restriction enzymes XhoI and SmaI.

299 **Protein expression and purification**

300 The COVID-19 virus RBD recombinant protein was expressed in *E.coli* as inclusion 301 body and in Bac-to-Bac expression system as soluble protein, respectively. The 302 inclusion body was refolded and further purified by Superdex 200 Hiload 16/60 303 column (GE Healthcare) in 20 mM Tris, pH 9.0, 150 mM NaCl. Human ACE2 protein 304 was expressed in baculovirus expression system. The constructed pFastBac1 plasmids 305 were transformed into DH10Bac competent cells to generate recombinant bacmids. 306 The bacmids were transfected into sf9 cells to generate virus and then amplified the 307 virus and infected High five cells for protein expression. Both the soluble COVID-19 308 virus RBD and hACE2 were purified by HisTrap HP column (GE Healthcare) and 309 were further purified by size-exclusion chromatography with a Superdex 200 column 310 (GE Healthcare) in 20 mM Tris, pH 8.0, 150 mM NaCl.

The plasmids of B38 heavy chain and light chain were co-transfected into HEK293T cells to produce B38 IgG. The full-length of B38 were used in neutralization and animal experiments. B38 Fab were generated by papain digestion and further purified by Protein A column (GE Healthcare) as described before(*20*).

315 **Bio-Layer Interferometry (BLI)**

316 The antibody binding screening and the competitive binding of mAbs and hACE2 (or 317 between two antibodies) were measured by BLI using the Octet RED96 system 318 (FortéBio). All experiments were performed at $25\square$ °C, and the biosensors were 319 pre-equilibrated in a buffer containing 20 mM HEPES, pH7.4 and 150 mM NaCl and 320 0.005% (v/v) Tween-20 for 10min. For the antibody binding screening assay, 293T 321 cell derived antibodies supernatants were loaded onto AHC biosensors for 120 s and 322 flowed with 500 nM COVID-19 virus RBD or 1µM SARS-CoV RBD. To determine 323 the competitive characteristics, 10 µg/mL biotinylated COVID-19 virus RBD was 324 loaded onto streptavidin biosensors for 60 s, and flowed 300 nM of the first protein 325 (one antibody) for 240 s and the second protein (hACE2 or the second antibody) for 326 240 s. The interference patterns from the biotinylated RBD with buffer and the 327 uncoated biosensors with protein were analyzed as two sets of controls. We used 328 corrected data to compare the competitive characteristics by Octet data analysis 329 software.

330 Surface plasmon resonance (SPR)

The affinity between COVID-19 virus RBD and antibodies were measured at room temperature using a BIAcore 8K system. All proteins used for kinetic analysis were exchanged to the buffer of 20 mM HEPES, 150 mM NaCl, pH 7.4 and 0.005% (v/v) Tween-20. A CM5 chip (GE Healthcare) was coupled with anti-human Fc antibody to capture the antibodies at 8000 response units. Gradient concentrations of COVID-19 virus RBD (from 200 nM to 12.5 nM with 2-fold dilution) were then flowed over the

337 chip surface. After each cycle, the sensor surface was regenerated with Gly-HCl

³³⁸ pH1.7. The affinity was calculated with BIAevaluation software.

339 Crystal screening and structure determination

340 The COVID-19 virus RBD protein and B38-Fab fragment were mixed at a molar 341 ration of 1:1.2. The mixture was incubated on ice for 60 min and further purified by 342 Superdex-200 column (GE Healthcare). 5 mg/mL and 10 mg/mL of hCoV-19 343 RBD/B38 Fab proteins were used for crystal screening by vapor-diffusion sitting-drop 344 method at 18°C. Diffracting crystals were obtained in the condition consisting of 0.15 345 M ammonium sulfate, 0.1 M MES pH 6 and 15% w/v PEG 400. Diffraction data were 346 collected at Shanghai Synchrotron Radiation Facility (SSRF) BL17U (wavelength, 0.97919 Å). The crystals were cryo-protected by briefly soaking in reservoir solution 347 348 supplemented with 20% (v/v) glycerol before flash-cooling in liquid nitrogen. The 349 dataset was processed with HKL2000 software(21). The complex structure was 350 determined by the molecular replacement method using Phaser with our previously 351 reported hCoV-2 RBD structure (PDB code, 6LZG) and Fab structure (PDB code, 352 4TSA). The atomic models were completed with Coot(22) and refined with 353 phenix.refine in Phenix(23), and the stereochemical qualities of the final models were 354 assessed with MolProbity(24). Data collection, processing, and refinement statistics 355 are summarized in Table S1. All the figures were prepared with Pymol software 356 (http://www.pymol.org).

357 Neutralization assay

 10^4 Vero cells were seeded in a 96-well plate (Costar) per well 24 hours before

359 infection. On the day of infection, the cells were washed twice with PBS. Each mAb 360 was diluted 2-fold in cell culture medium (modified eagle medium). 40 µL of diluted 361 mAb (100 μ g/mL as initial concentration) was added to 40 μ L of cell culture medium containing 100 times the tissue culture infective dose (TCID₅₀) of the 362 363 BetaCoV/Shenzhen/SZTH-003/2020 strain virus on a 96-well plate in decuplicate and 364 incubated at 37 °C for 2 hours. The mixture was then added to cells and incubated at 365 37 °C. The cytopathic effect was examined for 5 days post-infection. The complete 366 absence of cytopathic effect in an individual culture well was defined as protection. The values of IC₅₀ were calculated using prism software (GraphPad). 367

368 Animal experiments

369 Twelve female hACE2 transgenic mice (5-6 weeks old) were divided into three 370 groups with four mice in each group. All the mice were anaesthetized with thibromoethanol and then intranasally inoculated with $50\mu L \ 1*10^5 \ TCID_{50}/mL$ 371 372 COVID-19 virus (HB-01). After 12 hours, mice received a dose of 25 mg/kg B38 or H4 i.p. in a volume of 100 µL, an equivalent volume of PBS was administered as a 373 374 control. Body weights were monitored and recorded for four days. All the mice were 375 euthanized at 3 dpi. The lung homogenates were prepared in 1 mL DMEM and then 376 centrifuged at 3000 rpm for 10 min at 4 \Box . The supernatant was collected to extract 377 viral RNA by using the QIAamp Viral RNA Mini Kit (Qiagen). RNA was eluted in 80 378 μ L elution buffer, and 5 μ L was taken as the template for the quantitative real-time 379 reverse transcription-PCR (qRT-PCR) by rRT-PCR kit (Mabsky Biotech Co., Ltd., 380 CONFORMITE EUROPEENNE NO. DE/CA20/IVD-luxuslebenswelt-68/20). The

381 primers Ν followed: F: targeting used gene were as 382 5'-ATTGGCATGGAAGTCACACCTTC-3', R: 383 5'-TGCTTATTCAGCAAAATGACTTGAT-3', probe: 384 FAM--TGGTTGACCTACACAGGTGCCATCA--BHQ1. The amplification was performed as followed steps: 50 \square for 30 min, 95 \square for 3 min, followed by 45 cycles 385 386 at 95 \square 5 s and 55 \square for 30 s. This mice model was established and supplied by 387 Institute for Laboratory Animal Resources, NIFDC.

388

389 Acknowledgements

390 We thank the staff of the BL17U1 beamline at Shanghai Synchrotron Radiation 391 Facility (SSRF) for data collection. This work was supported by Zhejiang University 392 scientific research fund for COVID-19 prevention and special control 393 (2020XGZX019), National the Science and Technology Major Project 394 (2018ZX10733403), the National Key R&D Program of China (2018YFC1200603), 395 the National Key Plan for Scientific Research and Development of China 396 (2016YFD0500304), National Natural Science Foundation of China (31872745 and 397 81902058), and the National Science and Technology Major Projects of Infectious 398 Disease Funds (2017ZX10304402).

399 Author contributions

400 Y.W., F.G., G.F.G. and L.L. initiated and coordinated the project. Y.W., F.G. and

- 401 G.F.G designed the experiments. Y.L. and L.L. provided the convalescent PBMCs.
- 402 Y.W. and C.S performed the cell sorting. W.P., C.Z, Z.L. and C.G.S. sequenced and 403 constructed the antibodies. Y.W. conducted the SPR and Octet analysis with the help

- 404 of F.Z., F.W., Z.L. and Q.W.. C.S. and Y.Y. evaluated the neutralizing potency. S.L.
- and Y.B. conducted the animal experiments with the help from G.W., W.T., X.L. C.F.
- and H.X.. qRT-PCR was conducted by Y.G.. F.W., W.P. D.L. C.Z. and Z.L expressed
- and purified proteins. J.Q. and F.G. collected the diffraction dada and determined the
- 408 complex structure. Y.W., F.G. and G.F.G. analyzed the data and wrote the manuscript.
- 409 S.T. revised the manuscript.
- 410 **Competing interests**
- 411 Y.W., F.W., C.S., D.L., S.T., Y.L, G.F.G and L.L. are listed as inventors on pending
- patent applications for mAb B38 and H4. The other authors declare that they have nocompeting interests.
- 414 **Data availability statements**
- All the data and reagents presented in this study are available from the correspondingauthors upon request.
- 417 **Figure legends**

418 Figure 1. Characterization of COVID-19 virus specific neutralizing antibodies.

419 (A-D) The binding kinetics of the four antibodies (B38, H4 B5 and H2) with

420 COVID-19 virus RBD were measured by using a single-cycle BIAcore 8K system.

421 The antibodies were captured on a CM5 chip coupled with anti-human Fc antibody.

- 422 The COVID-19 RBD was serially diluted and injected with single-cycle kinetics
- 423 procedure. The binding affinity (Kd) was labeled accordingly. (E-H) Competition
- binding to the COVID-19 virus RBD between antibody and ACE2 was measured by
- 425 BLI in OctetRed96. Biotinylated COVID-19 virus RBD (10 µg/mL) were

426	immobilized on SA sensors. The SA sensors were saturated with antibodies, and then
427	flowed with corresponding antibody in the presence of 300 nM soluble ACE2 (blue)
428	or without ACE2 (red). As a control, the immobilized biotinylated COVID-19 virus
429	RBD was first flowed with buffer, and then flowed with the equal molar of ACE2
430	(black). (I) hACE2-EGFP was expressed on the HEK293T cell surface, and the cells
431	were stained with 200 ng/mL COVID-19 virus RBD his-tag proteins pre-incubated
432	with isotype IgG, B38, H4, B5 or H2. The percentage of both anti-histag APC^+ and
433	EGFP ⁺ cells were calculated. (J-K) Competition binding to COVID-19 virus RBD
434	between B38 and H4 was measured by BLI. Immobilized COVID-19 virus RBD (10
435	μ g/mL) were saturated with 300 nM of the first antibody, and then flowed with equal
436	molar of the first antibody in the presence of (blue) or without (red) the second
437	antibody. As a control, the immobilized COVID-19 RBD was first flowed with buffer,
438	and then flowed with the second antibody (black).
439	Figure 2. Four antibodies can effectively neutralize COVID-19 virus. The
440	mixtures of SARS-CoV-2 and serially diluted antibodies were added to Vero E6 cells.
441	After 5 days incubation, IC ₅₀ were calculated by fitting the CPE from serially diluted

antibody to a sigmoidal dose-response curve. The IC_{50} were labeled accordingly.

Figure 3. The protection efficiency of mAbs in hACE2 mice model post infection with COVID-19 virus. (A) Body weight loss were recorded for PBS (n=4), B38 treatment (n=4) and H4 treatment (n=4) groups. All the mice were challenged intranasally with COVID-19 virus, and 25 mg/kg antibodies were injected (i.p.) 12 hours post-infection. Equal volume of PBS was used as a control. The weight loss was recorded over three days, and the significant difference can be observed between B38 group and PBS group (unpaired *t*-test, ***p<0.001). (B) The virus titer in lungs of three groups were determined at 3 dpi by qRT-PCR. The mAb treatment group can reduce the viral load in the lung of mice (unpaired *t*-test, ***p<0.001).

452 Figure 4. Structural analysis of B38 and COVID-19 virus RBD complex and the 453 epitope comparison between B38 and hACE2. (A) The overall structure of B38 Fab 454 and COVID-19 virus RBD complex. The B38 heavy chain (cyan), light chain (green) 455 and COVID-19 virus RBD (magenta) are displayed in cartoon representation. (B) The 456 epitope of B38 are shown in surface representation. The contacted residues by heavy 457 chain, light chain or both are colored in cyan, green and magenta, respectively. The 458 identical residues on RBD involved in binding to both B38 and hACE2 are labeled in 459 red. (C) Superimposition of B38/COVID-19 virus RBD and hACE2/COVID-19 virus 460 RBD (PDB: 6LZG). All the molecules are presented in cartoon, with the same colors in panel A. hACE2 is colored in light pink. (D) The residues involved in hACE2-RBD 461 462 binding are highlighted in light pink. The identical residues on RBD involved in 463 binding to both B38 and hACE2 are labeled in red. (E) The complex structure of 464 SARS-CoV RBD (light blue) and hACE2 (yellow) (PDB:2AJF). (F) The residues of 465SARS-CoV RBD in contact with hACE2 are colored in yellow. The residues are 466 numbered according to SARS-CoV RBD. The identical residues involved in hACE2 467 binding of two RBDs are labeled in red. (G-I) The detailed interactions between 468 COVID-19 virus RBD and HCDR loops. (J-K) The detailed interactions between 469 COVID-19 virus RBD and LCDR loops. The residues are shown in sticks with the

470 identical colors to figure 3C. The water molecules are displayed in red sphere.

















L492/L478

P491/P477

F490/W476







E484/P469

P470